VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 295 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2018. The put-call ratio across all filers is 2.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $1,686,000 | -61.9% | 105,920 | -65.7% | 0.07% | -58.9% |
| Q3 2017 | $4,420,000 | +139.6% | 308,500 | +189.1% | 0.18% | +125.0% |
| Q2 2017 | $1,845,000 | -47.4% | 106,704 | -66.4% | 0.08% | -47.4% |
| Q1 2017 | $3,506,000 | -3.2% | 317,899 | +27.4% | 0.15% | -29.6% |
| Q4 2016 | $3,621,000 | +4.8% | 249,435 | +77.3% | 0.22% | -7.7% |
| Q3 2016 | $3,454,000 | -55.5% | 140,719 | -63.5% | 0.23% | -54.9% |
| Q2 2016 | $7,769,000 | +17.7% | 385,788 | +53.7% | 0.52% | -1.3% |
| Q1 2016 | $6,600,000 | -67.3% | 250,955 | +26.2% | 0.53% | -66.8% |
| Q4 2015 | $20,207,000 | +523.7% | 198,799 | +994.2% | 1.58% | +564.7% |
| Q3 2015 | $3,240,000 | +64.8% | 18,168 | +105.3% | 0.24% | +44.2% |
| Q2 2015 | $1,966,000 | +159.0% | 8,851 | +131.4% | 0.16% | +87.5% |
| Q1 2015 | $759,000 | -66.0% | 3,825 | -75.5% | 0.09% | -67.5% |
| Q4 2014 | $2,234,000 | – | 15,613 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACCIPITER CAPITAL MANAGEMENT, LLC | 2,373,210 | $47,796,000 | 39.06% |
| Claren Road Asset Management, LLC | 77,527 | $1,561,000 | 18.46% |
| Okumus Fund Management Ltd. | 4,242,012 | $85,434,000 | 14.79% |
| Chou Associates Management | 1,446,843 | $29,139,000 | 11.12% |
| FARLEY CAPITAL L.P. | 307,458 | $6,192,000 | 9.65% |
| HAP Trading, LLC | 3,129,700 | $112,397,000 | 6.58% |
| Pershing Square Capital Management | 21,591,122 | $434,845,000 | 5.79% |
| NORTH TIDE CAPITAL, LLC | 2,500,000 | $50,350,000 | 5.61% |
| Convector Capital Management, LP | 192,000 | $3,867,000 | 5.34% |
| Nebula Capital Management, LP | 31,770 | $640,000 | 5.07% |